Datar Cancer Genetics (DCG) has launched a revolutionary video reporting service for in vitro chemosensitivity testing, powered by AI-based technology. This innovation provides oncologists with real-time visual evidence of the efficacy of chemotherapy drugs on a patient's tumor cells, derived from tissue or blood biopsies. This approach addresses a critical need in precision oncology by offering concrete evidence to guide chemotherapy drug selection, ensuring that treatments are tailored to each patient.

 DCG's advanced platform uses human-supervised AI to analyze high-resolution, real-time videos of tumor cells exposed to chemotherapy drugs. These time-lapse videos provide clear and verifiable evidence to support treatment decisions. "For the first time, we can see how a patient's cancer cells respond to various chemotherapy treatments prior to administration," said Dr. Darshana Patil, senior director of Global Strategy and Medical Affairs.

Chemotherapy remains a cornerstone of cancer treatment, but treatment often fails due to empirical drug selection. The absence of molecular biomarkers for many drugs increases the risks of ineffectiveness and adverse effects. DCG's platform bridges this gap, improving decision-making and outcomes by reducing the risks associated with ineffective therapies.